- Poster presentation
- Open Access
Conditional inactivation of the ectodomain shedding of pro-TNFα in monocytes prevents lethality from LPS-induced septic shock
© Horiuchi et al.; licensee BioMed Central Ltd. 2012
- Published: 29 February 2012
- Endotoxin Shock
- Strong Protection
- Conditional Inactivation
- Principal Enzyme
TNFα is synthesized as a membrane-bound precursor and proteolytically released from cells. Soluble TNFα is the primary mediator of pathologies such as rheumatoid arthritis, Crohn's disease, and endotoxin shock. Although several different enzymes have been implicated in this proteolytic activity, recent studies lean toward the TNFα converting enzyme (TACE/ADAM17) as the most relevant TNFαsheddase in vivo. In the present study, we asked whether the inactivation TACE could yield a protection from lipopolysaccharide(LPS)-induced septic shockin mice.
To abrogate TNFα shedding activity in vivo, we generated conditional TACE-deficient mice using Cre-loxP system . We mated these mice with Mx1-Cre tg mice and LysM-Cre tg mice to inactivate TACE in BM cells and macrophage/monocyte lineage cells, respectively. Endotoxin shock was induced by i.p. injection of 5 μg of LPS and 20 mg of D-galactosamine. All injected mice were closely monitored every hour for the first 16 h and every 3-6 h thereafter.
We found that temporal disruption of TACE under the control of Mx1 transgene prevented lethality from endotoxin shock. Furthermore, inactivation of TACE in macrophage/monocyte lineage cells also rendered significant protection against LPS-induced septic shock. Consistent with these findings, serum TNFα levels in the TACE mutant mice were much lower than those in control mice. The present study thus shows that 1) TACE is indeed a principal enzyme responsible for the release of soluble TNFα in vivo, and that 2) inactivation of TACE in macrophage/monocyte lineage cells is sufficient to yield strong protection against LPS-induced endotoxin shock. Taken together, the present data indicate inhibition of TACE activity as a potential therapeutic target for TNFα-related disorders.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.